OBI Pharma (4174.TWO), partner to Biosion Inc., has announced that it has received approval from the US Food and Drug Administration (FDA) to proceed with a Phase I/II study for its novel antibody drug conjugate (ADC) cancer therapy, OBI-992, which targets TROP2.
The antibody molecules utilized in the development of this ADC were discovered and developed using Biosion’s proprietary SynTracer high-throughput antibody endocytosis screening platform and were licensed to OBI Pharma in December 2021. OBI-992 (BSI-992) incorporates a differentiated hydrophilic, enzyme-cleavable linker that maintains stability in circulation but releases the cytotoxic payload within tumor cells. The therapy has shown remarkable antitumor efficacy, improved pharmacokinetic characteristics, and a favorable safety profile in animal models. While Biosion discovered and developed the anti-TROP-2 targeting antibody, OBI Pharma holds the ex-China commercial rights for OBI-992 (BSI-992).- Flcube.com
